I like your numbers but $100m revenue won't be achieved in 1-2 years IMO.
To reach that will take some time but if revenues increase substantially each quarter, the market will take notice and revalue this accordingly.
If they can get to $10-$20m revenue for 2017, they will be doing well IMO.
Take a look at Pharmaxis with its EMA approval for Bronchitol. Revenues aren't impressive.
Obv FDA approval will be huge if Clinuvel are successful in Europe.
Ann: SCENESSE Treatment in Europe-CUV.AX, page-4
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.68 |
Change
-0.240(1.61%) |
Mkt cap ! $735.1M | |||
| Open | High | Low | Value | Volume |
| $14.75 | $14.92 | $14.65 | $503.5K | 34.18K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 448 | $14.68 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.74 | 149 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| CUV (ASX) Chart |